FDA Extends Trikafta Approval to Even Younger Cystic Fibrosis Patients
The FDA expanded the indication for elexacaftor, tezacaftor, and ivacaftor (Trikafta) in cystic fibrosis to include even younger children, maker Vertex Pharmaceuticals announced. The three-drug combination’s expanded label now covers children ages 2 to 5 years who have cystic fibrosis and either a F508del mutation in the CFTR gene or a CFTR gene mutation that […]
Unhealthy Lifestyle Factors Into Idiopathic Pulmonary Fibrosis
Lifestyle habits may contribute to individual risk for idiopathic pulmonary fibrosis (IPF), researchers found in the U.K. Biobank. In comparison to more “favorable” lifestyles, an “unfavorable” lifestyle was associated with a greater IPF risk (HR 2.271, 95% CI 1.852-2.785), as was an “intermediate” lifestyle (HR 1.384, 95% CI 1.218-1.574), reported Yaohua Tian, PhD, of Tongji […]
Diagnosis, Death in Pulmonary Fibrosis Seen Earlier in Black Patients
Black patients with pulmonary fibrosis (PF) consistently experienced poor outcomes associated with their disease at earlier ages than other groups, including hospitalization and death, according to U.S. registry data spanning nearly two decades. In an analysis from the Pulmonary Fibrosis Foundation Registry (PFFR) from 2003 to 2021, a PF diagnosis in Black individuals occurred about […]